How can clinicians treat patients with evidence-based methods when they do not reflect the reality they see every day in their practice? More often than not, physicians are faced making clinical decisions based on a little evidence to support a patient. Many patients already self-treat symptoms—ranging from insomnia, to anxiety, to depression—using cannabinoids, especially cannabidiol (CBD).
What evidence is there that this will help? What are the risks? What doses of CBD should they be using? What route? How will CBD interact with other medications? Andrew Penn, RN, MS, NP, CNS, APRN-BC will be exploring these questions in his talk “Confused about Cannabidiol: A Scientific and Rational Examination of its Risks and Benefits in Psychiatry” at Psych Congress in San Diego, California next month.
Dr. Penn will begin by reviewing the endocannabinoid system and its role in fine-tuning multiple other neurotransmitter systems. Many physicians aren’t as knowledgeable about the endocannabinoid system as they are with more well-known systems such as serotonin. But having a basic understanding of the CB1 receptors and the two primary endocannabinoid neorotransmitters: anandamide (AEA) and 1-Arachidonoylglycerol (2-AG) and the overall understanding of the compounds and function of Cannabis is critical to be able to effectively treat—and even more importantly, emotionally connect to—patients struggling with a variety disorders.
Join the conversation about CBD at the Psyche Congress on October 4th
Confused About Cannabidiol (CBD)? A Scientific and Rational Examination of Its Risks and Benefits in Psychiatry
